Since immunology has a central role in HER2-positive breast cancer and targeted treatment acts through immune-mediated mechanisms [5], we speculate that the presence of liver metastases would accordingly be associated with adverse prognosis and specific tumour immune profiles of the primary tumour. Here, ERBB2 is linked to breast carcinoma.